膀胱癌根治性膀胱切除术后癌症与全因死亡列线图的开发与验证
利用监测、流行病学和最终结果-医疗保险(SEER-Medicare)及德克萨斯癌症登记-医疗保险链接数据,纳入临床分期T2-T4a肌层浸润性膀胱癌患者,开发并外部验证预测根治性膀胱切除术后3年和5年总生存与癌症特异性生存的列线图,验证队列一致性指数分别为0.65和0.66。
要点
- 接受根治性膀胱切除术的患者相比未接受者更年轻、男性居多、已婚、非西班牙裔白人且合并症更少(P < .001)。
- 已婚患者较未婚者总生存(HR 0.76;95%CI 0.70-0.83,P < .001)和癌症特异性生存(HR 0.76;95%CI 0.68-0.85,P < .001)均改善。
- 列线图在德克萨斯癌症登记-医疗保险验证队列中预测3年和5年总生存与癌症特异性生存的一致性指数分别为0.65和0.66。
核心结论
- 年龄较大、未婚且合并症较多的患者较少接受根治性膀胱切除术。
- 开发并验证了一个可推广的工具,已转化为在线工具(根治性膀胱切除术生存计算器),为考虑根治性膀胱切除术的患者提供获益-风险评估。
研究设计与样本
- 使用SEER-Medicare和德克萨斯癌症登记-医疗保险链接数据,分别纳入5325例和1257例2006年1月1日至2011年12月31日诊断为临床分期T2-T4a肌层浸润性膀胱癌的患者。
- 采用Cox比例风险模型开发列线图,预测3年和5年总生存与癌症特异性生存,并进行外部验证。
主要发现
- 接受根治性膀胱切除术的患者相比未接受者更年轻、男性居多、已婚、非西班牙裔白人且合并症更少(P < .001)。
- 已婚患者较未婚者总生存改善(HR 0.76;95%CI 0.70-0.83,P < .001)。
- 已婚患者较未婚者癌症特异性生存改善(HR 0.76;95%CI 0.68-0.85,P < .001)。
- 基于SEER-Medicare数据开发的列线图在德克萨斯癌症登记-医疗保险验证队列中预测3年和5年总生存与癌症特异性生存的一致性指数分别为0.65和0.66。
临床怎么用
- 作者开发并验证的在线工具(根治性膀胱切除术生存计算器)可用于为考虑根治性膀胱切除术的患者提供获益-风险评估。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To develop and validate a nomogram assessing cancer and all-cause mortality following radical cystectomy. Given concerns regarding the morbidity associated with surgery, there is a need for incorporation of cancer-specific and competing risks into patient counseling and recommendations. MATERIALS AND METHODS: A total of 5325 and 1257 diagnosed with clinical stage T2-T4a muscle-invasive bladder cancer from January 1, 2006 to December 31, 2011 from Surveillance, Epidemiology, and End Results-Medicare and Texas Cancer Registry-Medicare linked data, respectively. Cox proportional hazards models were used and a nomogram was developed to predict 3- and 5-year overall and cancer-specific survival with external validation. RESULTS: Patients who underwent radical cystectomy were mostly younger, male, married, non-Hispanic white and had fewer comorbidities than those who did not undergo radical cystectomy (P < .001). Married patients, in comparison with their unmarried counterparts, had both improved overall (hazard ratio 0.76; 95% confidence interval 0.70-0.83, P < .001) and cancer-specific (hazard ratio 0.76; 95% confidence interval 0.68-0.85, P < .001) survival. A nomogram developed using Surveillance, Epidemiology, and End Results-Medicare data, predicted 3- and 5-year overall and cancer-specific survival rates with concordance indices of 0.65 and 0.66 in the validated Texas Cancer Registry-Medicare cohort, respectively. CONCLUSION: Older, unmarried patients with increased comorbidities are less likely to undergo radical cystectomy. We developed and validated a generalizable instrument that has been converted into an online tool (Radical Cystectomy Survival Calculator), to provide a benefit-risk assessment for patients considering radical cystectomy.
引用
- Williams SB, Huo J, Chu Y, et al. Cancer and All-cause Mortality in Bladder Cancer Patients Undergoing Radical Cystectomy: Development and Validation of a Nomogram for Treatment Decision-making. Urology. 2017. PMID: 28847688. doi:10.1016/j.urology.2017.08.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。